Abstract
AbstractAbstract 4618c-Myc (hereafter Myc) overexpression has been recognized in aggressive B-cell lymphomas and linked to adverse prognosis. Myc activation results in widespread repression of miRNA expression and lymphoma aggressive progression. Our recent study identified a Myc-miRNAs-EZH2 feed-forward loop linking over-expression of Myc, EZH2, and miRNA repression. Here, using a novel small-molecule bromodomain inhibitor, JQ1, to silence Myc and the EZH2 inhibitor DZNep, we demonstrated that combined inhibition of Myc and EZH2 cooperatively disrupted Myc activation, resulting in restoration of miR-26a expression, which subsequently suppressed lymphoma growth and clonogenicity in aggressive lymphoma cells. Furthermore, Myc and EZH2 cooperatively regulated miR-26a expression in aggressive lymphoma cells. MiR-26a functioned as a tumor suppressor miRNA and mediated the combinatorial effect of JQ1 and DZNep. These findings represent a promising, novel approach for silencing Myc with JQ1 for combinatorial therapy of aggressive B-cell lymphomas. Disclosures:No relevant conflicts of interest to declare.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
